MX2016004575A - Metodos de modificacion de celulas huespedes. - Google Patents

Metodos de modificacion de celulas huespedes.

Info

Publication number
MX2016004575A
MX2016004575A MX2016004575A MX2016004575A MX2016004575A MX 2016004575 A MX2016004575 A MX 2016004575A MX 2016004575 A MX2016004575 A MX 2016004575A MX 2016004575 A MX2016004575 A MX 2016004575A MX 2016004575 A MX2016004575 A MX 2016004575A
Authority
MX
Mexico
Prior art keywords
methods
host cell
cell modification
host cells
nucleic acid
Prior art date
Application number
MX2016004575A
Other languages
English (en)
Other versions
MX371513B (es
Inventor
Michael Wacker
Michael Kowarik
Fabiana Fernandez
Original Assignee
Glycovaxyn Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycovaxyn Ag filed Critical Glycovaxyn Ag
Publication of MX2016004575A publication Critical patent/MX2016004575A/es
Publication of MX371513B publication Critical patent/MX371513B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1051Hexosyltransferases (2.4.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0258Escherichia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0283Shigella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/104Pseudomonadales, e.g. Pseudomonas
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/00041Use of virus, viral particle or viral elements as a vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/30Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En la presente se describen métodos para insertar secuencias de ácidos nucleicos en las células huéspedes. También se describen en la presente células huéspedes genéticamente estables que comprenden secuencias de ácidos nucleicos insertadas y los métodos para utilizar estas células huéspedes en la generación de las proteínas.
MX2016004575A 2013-10-11 2014-10-13 Metodos de modificacion de celulas huespedes. MX371513B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361889672P 2013-10-11 2013-10-11
PCT/EP2014/071889 WO2015052344A1 (en) 2013-10-11 2014-10-13 Methods of host cell modification

Publications (2)

Publication Number Publication Date
MX2016004575A true MX2016004575A (es) 2016-07-12
MX371513B MX371513B (es) 2020-01-31

Family

ID=51726490

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004575A MX371513B (es) 2013-10-11 2014-10-13 Metodos de modificacion de celulas huespedes.

Country Status (13)

Country Link
US (2) US11220676B2 (es)
EP (1) EP3055416B1 (es)
JP (1) JP2016533719A (es)
KR (1) KR20160062169A (es)
CN (1) CN106062203B (es)
BR (1) BR112016007727A8 (es)
CA (1) CA2926523C (es)
EA (1) EA201690529A1 (es)
ES (1) ES2778074T3 (es)
IL (1) IL244791A0 (es)
MX (1) MX371513B (es)
SG (1) SG11201602546RA (es)
WO (1) WO2015052344A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX365331B (es) 2013-01-17 2019-05-29 Arsanis Biosciences Gmbh Anticuerpo específico contra e. coli mdr.
WO2015052344A1 (en) 2013-10-11 2015-04-16 Glycovaxyn Ag Methods of host cell modification
CA2940547C (en) 2014-02-24 2021-01-05 Glycovaxyn Ag Novel polysaccharide and uses thereof
BR112016023688B1 (pt) * 2014-04-17 2024-01-09 Glaxosmithkline Biologicals Sa Bioconjugado e uso de um bioconjugado
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201712678D0 (en) 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
EP3492482A1 (en) 2017-11-30 2019-06-05 Vaxxilon AG Vaccine against klebsiella pneumoniae
CN108611306B (zh) * 2018-04-03 2021-05-25 华南农业大学 一种研究慢生根瘤菌的基因功能的方法
CN108531439B (zh) * 2018-04-16 2020-04-07 南京工业大学 一种大肠杆菌基因工程菌及其构建方法与应用
CN108774628B (zh) * 2018-07-02 2022-03-25 南开大学 合成致新生儿脑膜炎大肠杆菌糖蛋白结合疫苗的大肠杆菌工程菌及用途
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EA202192390A1 (ru) 2019-03-18 2021-12-03 Янссен Фармасьютикалз, Инк. Биоконъюгаты полисахаридных о-антигенов e.coli, способы их получения и способы их применения
AU2020240075A1 (en) 2019-03-18 2021-10-14 Janssen Pharmaceuticals, Inc. Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
JP2021000041A (ja) * 2019-06-24 2021-01-07 トヨタ自動車株式会社 形質転換補助用プラスミド及びこれを用いた形質転換体の製造方法、並びに形質転換方法
EP4107170A2 (en) * 2020-02-23 2022-12-28 Pfizer Inc. Escherichia coli compositions and methods thereof
KR102160203B1 (ko) * 2020-06-15 2020-09-25 서울시립대학교 산학협력단 데이노잔틴 고생산능을 갖는 변이 균주의 제조방법 및 온도제어를 이용한 데이노잔틴 대량생산 방법
CA3185639A1 (en) 2020-06-25 2021-12-30 Glaxosmithkline Biologicals Sa Vaccine
JP7517002B2 (ja) 2020-09-10 2024-07-17 トヨタ自動車株式会社 形質転換体の製造方法及び形質転換方法
WO2022058945A1 (en) 2020-09-17 2022-03-24 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
IL302362A (en) * 2020-10-27 2023-06-01 Pfizer ESCHERICHIA COLI preparations and their methods
JP2022087881A (ja) * 2020-12-02 2022-06-14 トヨタ自動車株式会社 形質転換用プラスミド及びこれを用いた形質転換体の製造方法、並びに形質転換方法
JP2022099381A (ja) * 2020-12-23 2022-07-05 トヨタ自動車株式会社 形質転換補助用プラスミド及びこれを用いた形質転換体の製造方法、並びに形質転換方法
JP2022099419A (ja) * 2020-12-23 2022-07-05 トヨタ自動車株式会社 形質転換用プラスミド及びこれを用いた形質転換体の製造方法、並びに形質転換方法
CN113388596B (zh) * 2021-08-16 2021-12-07 翌圣生物科技(上海)股份有限公司 高保真Pfu DNA聚合酶突变体、其编码DNA及其在NGS中的应用
JP2024139548A (ja) * 2023-03-27 2024-10-09 株式会社豊田中央研究所 遺伝子発現方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2353814T3 (es) * 2005-05-11 2011-03-07 Eth Zuerich Proteinas n-glicosiladas recombinantes de celulas procariotas.
CN101983070B (zh) * 2008-02-20 2016-03-30 格林考瓦因有限公司 由来源于原核细胞的重组n-糖基化蛋白制备生物共轭物
GB0915403D0 (en) 2009-09-04 2009-10-07 London School Hygiene & Tropical Medicine Protein glycosylation
DK2501406T3 (en) * 2009-11-19 2018-02-26 Glaxosmithkline Biologicals Sa BIOSYNTHESE SYSTEM PRODUCING IMMUNOGENIC POLYSACCHARIDES IN PROCARYOTIC CELLS
KR20130063510A (ko) * 2010-05-06 2013-06-14 글리코박신 아게 캡슐형 그람-양성 세균 생체접합체 백신
US20140336366A1 (en) * 2011-09-06 2014-11-13 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
KR20140091017A (ko) 2011-10-28 2014-07-18 머크 샤프 앤드 돔 코포레이션 Alg3 발현이 결핍된 피키아 파스토리스 균주에서 n-글리칸 점유율을 증가시키고 하이브리드 n-글리칸의 생산을 감소시키는 방법
WO2014037585A1 (en) * 2012-09-10 2014-03-13 Glycovaxyn Ag Bioconjugates comprising modified antigens and uses thereof
CA2887133C (en) * 2012-10-12 2022-05-03 Glycovaxyn Ag Methods of host cell modification
CN105008539B (zh) 2012-11-07 2020-04-17 葛兰素史密丝克莱恩生物有限公司 通过酶缀合在大肠杆菌中生产重组疫苗
WO2015052344A1 (en) 2013-10-11 2015-04-16 Glycovaxyn Ag Methods of host cell modification

Also Published As

Publication number Publication date
CN106062203B (zh) 2020-08-07
CA2926523C (en) 2023-09-26
US20170121691A1 (en) 2017-05-04
KR20160062169A (ko) 2016-06-01
IL244791A0 (en) 2016-04-21
CN106062203A (zh) 2016-10-26
EP3055416A1 (en) 2016-08-17
BR112016007727A8 (pt) 2018-01-30
JP2016533719A (ja) 2016-11-04
US11220676B2 (en) 2022-01-11
ES2778074T3 (es) 2020-08-07
BR112016007727A2 (pt) 2017-09-12
CA2926523A1 (en) 2015-04-16
MX371513B (es) 2020-01-31
SG11201602546RA (en) 2016-04-28
EP3055416B1 (en) 2020-01-22
US20220186196A1 (en) 2022-06-16
EA201690529A1 (ru) 2016-11-30
WO2015052344A1 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
MX371513B (es) Metodos de modificacion de celulas huespedes.
MX365435B (es) Metodos de modificacion de celulas huesped.
GB2569733A (en) RNA-guided nucleic acid modifying enzymes and methods of use thereof
MX2022002624A (es) Edicion del genoma sin nucleasas.
BR112017014031A2 (pt) n-oligossacaril-transferase recombinante, mutante de n-oligossacaril-transferase recombinante, ácido nucleico, célula hospedeira, e, método para produção de um bioconjugado.
MX2019005158A (es) Variantes de glucoamilasa y polinucleotidos que las codifican.
MX2019013498A (es) Receptor de antigeno quimerico y metodos para usarlo.
TR201908404T4 (tr) İşlenmiş yüksek afinite insan t hücresi reseptörleri.
PH12016500395A1 (en) Cell penetrating conjugates and methods of use thereof
EA201992795A1 (ru) Способ получения эукариотических клеток с отредактированной днк и набор, используемый в этом способе
MX2016007797A (es) Metodos para integracion genomica.
IN2014CN03468A (es)
IN2014DN05963A (es)
GB2561496A (en) Devices and methods for simulating a function of a liver tissue
IL241294A0 (en) Genetic expression of response in dendritic cells, preparations and methods of use
WO2014116846A3 (en) Methods and compositions for modulating an immune response
MY197877A (en) Rna-guided transcriptional regulation
GB2562396A (en) Devices for simulating a function of a liver tissue and methods of use and manufacturing thereof
MX337984B (es) Variantes de alfa amilasa y polinucleotidos que codifican la misma.
MX370134B (es) Enzimas de cetol-acido reductoisomerasa y metodo de uso.
BR112012026379A2 (pt) métodos para gerar proteína endogenamente marcada
MX355356B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
MX354704B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
WO2014089268A3 (en) Lgr5+ somatic stem cells

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A.

FG Grant or registration